Global Liver Cirrhosis Treatment Market

Liver Cirrhosis Treatment Market Size, Share, Growth Analysis, By Treatment Modality(Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents), By Disease(Hepatitis, Non-alcoholic Fatty Liver Disease, Alcohol-induced, and Liver Cancer), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35A2887 | Region: Global | Published Date: May, 2024
Pages: 218 | Tables: 66 | Figures: 74

Liver Cirrhosis Treatment Market News

  • On January 31, 2022, Madrigal Pharmaceuticals saw an increase in premarket activity as the company delivered encouraging top-line data from the resmetirom study in non-alcoholic fatty liver disease.
  • On September 30, 2021, Livmarly, Mirum’s minimally absorbed ileal bile acid transport (iBAT) inhibitor, received FDA approval. Emerging antibiotics are the first-line treatment for the disease, which affects 2,000–2,500 young people in the United States.
  • January 2023: Takeda and Arrowhead Pharmaceuticals Inc. announced superior results of the Phase 2 SEQUOIA clinical trial of investigational fajirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Liver Cirrhosis Treatment Market size was valued at USD 17.76 Billion in 2023 and is poised to grow from USD 18.9 Billion in 2024 to USD 31.09 Billion by 2032, growing at a CAGR of 6.42% during the forecast period (2025-2032).

The competitive environment of the Global Liver Cirrhosis Treatment Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. The liver cirrhosis treatment market is fragmented, with several key players. In terms of market share, the market is currently dominated by a few major players. The companies currently dominating the market include Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi, Astellas Pharma, Inc. and others. 'Pfizer, Inc.', 'Merck & Co., Inc.', 'Novartis AG', 'Takeda Pharmaceuticals Company Ltd.', 'Zydus Pharmaceuticals, Inc.', 'Gilead Science, Inc.', 'Sanofi S.A.', 'AstraZeneca plc', 'GSK plc', 'AbbVie Inc.', 'Abbott Laboratories', 'Astellas Pharma Inc.', 'Bristol Myers Squibb', 'Eli Lilly and Company', 'F. Hoffman-LA Roche', 'Emergent BioSolutions (Cangene bioPharma)', 'Gilead Sciences, Inc.,', 'Merck & Co., Inc. (Merck Sharp & Dohme Corp.)', 'Viatris Inc.'

Liver disease is still very common worldwide. Due to sedentary lifestyle, inactivity and especially poor diet, many people are suffering from liver disease. The aging population is getting older, and autoimmune diseases such as hepatitis and non-alcoholic fatty liver are on the rise. We can also attribute the significant increase in cases to alcohol consumption greater than. Increasing availability of therapies for liver diseases will drive the global market for treatment of liver diseases. In response to increased demand for hepatitis treatment, healthcare organizations funded the development of new drugs, devices, and treatment options, supported by biotechnology and research institutes around the world greatly led to the development of new drugs for the treatment of liver disease. Due to the growth and development, the market for treatment of liver diseases will be highly competitive and prosperous. This is expected to open lucrative opportunities for market participants and accelerate market growth.

Rising Research and Development Efforts: Increasing R&D efforts to develop new therapies and therapeutic targets for liver disease, increasing services and funding for prevention, diagnosis and treatment of liver disease, increasing liver disease awareness, if needed the need for early diagnosis and healthcare costs. Increasing aging population, increasing awareness, improving healthcare infrastructure, increasing disposable income in emerging markets and increasing advancement in surgical procedures, procedures not taken more penetration and radiology interventions further support the growth of the market.

The largest regional market. cirrhosis of the liver is common in the United States. In the U.S. saw 88,000 deaths from alcohol-related liver disease and hepatitis. Additionally, the health care system in the U.S. has 88,000 deaths from alcohol-related liver disease is also growing, contributing to the growth of the global liver cirrhosis treatment market. Furthermore, Pfizer Inc. has a strong presence in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Liver Health Supplements Market
Buy Now GET FREE SAMPLE
Liver Cancer Drugs Market
Buy Now GET FREE SAMPLE
Continuous Renal Replacement Therapy Market
Buy Now GET FREE SAMPLE
Cod Liver Oil Market
Buy Now GET FREE SAMPLE
Bleeding Disorders Treatment Market
Buy Now GET FREE SAMPLE
Venous Thromboembolism Treatment Market
Buy Now GET FREE SAMPLE
Patient Portal Market
Buy Now GET FREE SAMPLE
Non-alcoholic Steatohepatitis Biomarkers Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Liver Cirrhosis Treatment Market

Report ID: SQMIG35A2887

$5,300
BUY NOW GET FREE SAMPLE